+

DK1053019T3 - Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra - Google Patents

Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra

Info

Publication number
DK1053019T3
DK1053019T3 DK99902172T DK99902172T DK1053019T3 DK 1053019 T3 DK1053019 T3 DK 1053019T3 DK 99902172 T DK99902172 T DK 99902172T DK 99902172 T DK99902172 T DK 99902172T DK 1053019 T3 DK1053019 T3 DK 1053019T3
Authority
DK
Denmark
Prior art keywords
degradable
gels
polyethylene glycol
derived therefrom
glycol acrylates
Prior art date
Application number
DK99902172T
Other languages
Danish (da)
English (en)
Inventor
J Milton Harris
Xuan Zhao
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Application granted granted Critical
Publication of DK1053019T3 publication Critical patent/DK1053019T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DK99902172T 1998-01-07 1999-01-06 Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra DK1053019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7068098P 1998-01-07 1998-01-07
PCT/US1999/000594 WO1999034833A1 (fr) 1998-01-07 1999-01-06 Acrylates de polyethyleneglycol heterobifonctionnel degradables, et gels et conjugues derives de ces acrylates

Publications (1)

Publication Number Publication Date
DK1053019T3 true DK1053019T3 (da) 2004-04-13

Family

ID=22096751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99902172T DK1053019T3 (da) 1998-01-07 1999-01-06 Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra

Country Status (11)

Country Link
US (7) US6362276B1 (fr)
EP (1) EP1053019B1 (fr)
JP (1) JP3786832B2 (fr)
AT (1) ATE255422T1 (fr)
AU (1) AU755051B2 (fr)
CA (1) CA2316834C (fr)
DE (1) DE69913316T2 (fr)
DK (1) DK1053019T3 (fr)
ES (1) ES2211033T3 (fr)
PT (1) PT1053019E (fr)
WO (1) WO1999034833A1 (fr)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
AU4648697A (en) 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK1053019T3 (da) * 1998-01-07 2004-04-13 Debio Rech Pharma Sa Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra
US7790192B2 (en) 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
GB2341185A (en) * 1998-09-07 2000-03-08 Polybiomed Ltd Polymerizable material and adhesive sheet material therefrom; dressings, electrodes and transdermal patches
AU6151799A (en) 1998-09-17 2000-04-03 Focal, Inc. Self-cleaning fluid delivery device for medical applications
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7744912B1 (en) 1999-02-01 2010-06-29 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6828412B1 (en) * 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
US6288184B1 (en) * 1999-09-29 2001-09-11 Sri International Hydrolytically degradable olefin copolymers
US7037992B2 (en) * 1999-09-29 2006-05-02 Sri International Olefin copolymers containing hydrolytically cleavable linkages and use thereof in degradable products
BR9917517A (pt) * 1999-10-08 2002-07-30 Shearwater Corp Derivados poliméricos heterobifuncionais e processo para a preparação dos mesmos
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
WO2002055185A2 (fr) 2000-10-19 2002-07-18 Eidgenoess Tech Hochschule Copolymeres blocs pour systemes auto-assembles multifonctionnels
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
ES2466024T3 (es) 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1531791B1 (fr) 2002-06-07 2010-08-11 Dyax Corp. Prevention et reduction de l'ischemie
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7217254B2 (en) 2002-09-20 2007-05-15 Genzyme Corporation Multi-pressure biocompatible agent delivery device and method
SI2891666T1 (sl) 2002-10-16 2017-11-30 Purdue Pharma L.P. Protitelesa, ki vežejo s celicami povezan antigen CA 125/O722P, in metoda za njihovo uporabo
US7311926B2 (en) * 2002-12-20 2007-12-25 Battelle Memorial Institute Biocomposite materials and methods for making the same
BRPI0408358A (pt) 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
BRPI0410164A (pt) 2003-05-09 2006-05-16 Neose Technologies Inc composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
EP1663281B1 (fr) * 2003-08-29 2013-12-25 Dyax Corp. Inhibiteurs de protease poly-pegylee
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
EP2332968B1 (fr) 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Peptides alpha-hélicaux pour l'activation ou l'inhibition de la mort cellulaire
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005061018A1 (fr) * 2003-12-22 2005-07-07 Regentis Biomaterials Ltd. Matrice comprenant un squelette proteique reticule naturel
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
WO2005070138A2 (fr) 2004-01-08 2005-08-04 Neose Technologies, Inc. Glycosylation de peptides liee a o
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1609491B1 (fr) 2004-06-16 2008-02-06 Straumann Holding AG Membrane barrière
US7282584B2 (en) 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
EP1625856A1 (fr) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel conjugé polymèrique d'une prodrogue
EP2594291A1 (fr) 2004-07-05 2013-05-22 Ascendis Pharma GmbH Hydrogel
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (fr) 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2006213822B2 (en) 2005-02-09 2011-05-26 Covidien Lp Synthetic sealants
US20060222596A1 (en) 2005-04-01 2006-10-05 Trivascular, Inc. Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
WO2006127910A2 (fr) 2005-05-25 2006-11-30 Neose Technologies, Inc. Formulations d'erythropoietine glycopegylees
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
WO2007007392A1 (fr) * 2005-07-11 2007-01-18 Wako Pure Chemical Industries, Ltd. Nouveau polymere et procede de mesure du taux de cholesterol utilisant ce polymere
EP1926768B1 (fr) 2005-07-18 2011-09-14 Nektar Therapeutics Polymeres fonctionnalises ramifies en utilisant des noyaux de polyol ramifies
GB0515625D0 (en) * 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007127198A2 (fr) 2006-04-24 2007-11-08 Incept, Llc Agents de réticulation de protéine, méthodes de réticulation et leurs applications
US7872068B2 (en) 2006-05-30 2011-01-18 Incept Llc Materials formable in situ within a medical device
WO2007149594A2 (fr) 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Ribonucléases modifiées
JP2009543868A (ja) * 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
WO2008011165A2 (fr) * 2006-07-21 2008-01-24 Nektar Therapeutics Al, Corporation Réactifs polymères comprenant un groupe vinylique terminal et conjugués formés à partir de ceux-ci
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2068907B1 (fr) 2006-10-04 2017-11-29 Novo Nordisk A/S Glycopeptides et sucres pegyles à liaison glycerol
US8394483B2 (en) 2007-01-24 2013-03-12 Micron Technology, Inc. Two-dimensional arrays of holes with sub-lithographic diameters formed by block copolymer self-assembly
WO2008095063A1 (fr) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilisés et utilisations de ceux-ci
US8083953B2 (en) 2007-03-06 2011-12-27 Micron Technology, Inc. Registered structure formation via the application of directed thermal energy to diblock copolymer films
US8557128B2 (en) 2007-03-22 2013-10-15 Micron Technology, Inc. Sub-10 nm line features via rapid graphoepitaxial self-assembly of amphiphilic monolayers
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
US8097175B2 (en) 2008-10-28 2012-01-17 Micron Technology, Inc. Method for selectively permeating a self-assembled block copolymer, method for forming metal oxide structures, method for forming a metal oxide pattern, and method for patterning a semiconductor structure
US8294139B2 (en) 2007-06-21 2012-10-23 Micron Technology, Inc. Multilayer antireflection coatings, structures and devices including the same and methods of making the same
US7959975B2 (en) 2007-04-18 2011-06-14 Micron Technology, Inc. Methods of patterning a substrate
US8372295B2 (en) 2007-04-20 2013-02-12 Micron Technology, Inc. Extensions of self-assembled structures to increased dimensions via a “bootstrap” self-templating method
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
EP2170919B8 (fr) 2007-06-12 2016-01-20 ratiopharm GmbH Procédé amélioré pour la production de sucres de nucléotide
US8404124B2 (en) 2007-06-12 2013-03-26 Micron Technology, Inc. Alternating self-assembling morphologies of diblock copolymers controlled by variations in surfaces
US8080615B2 (en) 2007-06-19 2011-12-20 Micron Technology, Inc. Crosslinkable graft polymer non-preferentially wetted by polystyrene and polyethylene oxide
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2205271B1 (fr) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions et procédés pour des thérapies à base de ribonucléase
US8999492B2 (en) 2008-02-05 2015-04-07 Micron Technology, Inc. Method to produce nanometer-sized features with directed assembly of block copolymers
EP2247645B1 (fr) * 2008-02-13 2017-12-06 Hyperbranch Medical Technology, Inc. Hydrogels à base de polyalkylèneimines réticulées à taux de dégradation ajustable
US8101261B2 (en) 2008-02-13 2012-01-24 Micron Technology, Inc. One-dimensional arrays of block copolymer cylinders and applications thereof
JP5150297B2 (ja) * 2008-02-14 2013-02-20 ネクター セラピューティックス エイエル，コーポレイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
CA2715465C (fr) 2008-02-27 2017-03-21 Novo Nordisk A/S Molecules de facteur viii conjuguees
US8425982B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Methods of improving long range order in self-assembly of block copolymer films with ionic liquids
US8426313B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Thermal anneal of block copolymer films with top interface constrained to wet both blocks with equal preference
US8114300B2 (en) 2008-04-21 2012-02-14 Micron Technology, Inc. Multi-layer method for formation of registered arrays of cylindrical pores in polymer films
US8114301B2 (en) 2008-05-02 2012-02-14 Micron Technology, Inc. Graphoepitaxial self-assembly of arrays of downward facing half-cylinders
US8575102B2 (en) * 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
JP5435536B2 (ja) * 2008-09-04 2014-03-05 学校法人神奈川大学 光分解性ブロックコポリマー
US9206223B2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
WO2010067378A2 (fr) 2008-12-08 2010-06-17 Reliance Life Sciences Pvt. Ltd. Composition d'hydrogel
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA2744088A1 (fr) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
CA2977830C (fr) 2009-05-04 2019-09-17 Incept, Llc Biomateriaux pour la fermeture de voie et de ponction
CN102458451B (zh) 2009-06-09 2016-10-05 普罗朗制药有限责任公司 血红蛋白组合物
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
JP4704506B2 (ja) * 2009-08-11 2011-06-15 財団法人川村理化学研究所 有機無機複合ヒドロゲルおよびその製造方法
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
US20110081398A1 (en) * 2009-10-01 2011-04-07 Tyco Healthcare Group Lp Multi-mechanism surgical compositions
US20110081701A1 (en) * 2009-10-02 2011-04-07 Timothy Sargeant Surgical compositions
US8968785B2 (en) * 2009-10-02 2015-03-03 Covidien Lp Surgical compositions
JP5552310B2 (ja) 2009-12-24 2014-07-16 日清紡ホールディングス株式会社 樹脂架橋剤
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
WO2012021875A1 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques à coupleurs triazole
US8304493B2 (en) 2010-08-20 2012-11-06 Micron Technology, Inc. Methods of forming block copolymers
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
WO2012065181A2 (fr) 2010-11-12 2012-05-18 Dana Farber Cancer Institute, Inc. Thérapies et diagnostics du cancer
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2852468A1 (fr) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
US8900963B2 (en) 2011-11-02 2014-12-02 Micron Technology, Inc. Methods of forming semiconductor device structures, and related structures
CA2862391C (fr) 2011-12-29 2023-10-10 Loren D. Walensky Helices hybrides stabilisees antivirales
WO2013123266A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP5953459B2 (ja) * 2012-03-27 2016-07-20 ネクター セラピューティクス ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
ES2874525T3 (es) 2012-09-26 2021-11-05 Harvard College Péptidos grapados bloqueados con prolina y usos de los mismos
US9087699B2 (en) 2012-10-05 2015-07-21 Micron Technology, Inc. Methods of forming an array of openings in a substrate, and related methods of forming a semiconductor device structure
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN110105434B (zh) 2013-03-13 2024-09-17 哈佛大学的校长及成员们 钉合且缝合的多肽及其用途
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2014144768A2 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides bh4 stabilisés et leurs utilisations
EP2970418A4 (fr) 2013-03-15 2016-08-17 Dana Farber Cancer Inst Inc Peptide d'ezh2 stabilisé
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9229328B2 (en) 2013-05-02 2016-01-05 Micron Technology, Inc. Methods of forming semiconductor device structures, and related semiconductor device structures
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
US9177795B2 (en) 2013-09-27 2015-11-03 Micron Technology, Inc. Methods of forming nanostructures including metal oxides
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
CN106795506B (zh) 2014-05-14 2020-11-27 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
CN111620940A (zh) 2014-05-21 2020-09-04 哈佛大学的校长及成员们 Ras抑制肽和其用途
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US11142554B2 (en) 2015-03-18 2021-10-12 Massachusetts Institute Of Technology Selective Mcl-1 binding peptides
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP3302547A1 (fr) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
WO2017004548A1 (fr) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
AU2016287754B2 (en) 2015-07-02 2021-02-25 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
US11078246B2 (en) 2015-08-28 2021-08-03 Dana-Farber Cancer Institute, Inc. Peptides binding to Bfl-1
EP3347372A4 (fr) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
JP6184462B2 (ja) * 2015-10-28 2017-08-23 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CA3014442A1 (fr) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Peptides antimicrobiens agrafes a ciblage intracellulaire pour traiter une infection
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
US11466064B2 (en) 2016-08-26 2022-10-11 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018170299A1 (fr) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs de transcription de gène procaryote et leurs utilisations
JP6361083B2 (ja) * 2017-06-27 2018-07-25 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US11325955B2 (en) 2017-07-19 2022-05-10 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
US11847932B2 (en) 2017-09-07 2023-12-19 Intuitive Surgical Operations, Inc. Modified animal organs for use in surgical simulators
US11834520B2 (en) 2017-12-15 2023-12-05 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
AU2018385697B2 (en) 2017-12-15 2023-11-09 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
CA3089279A1 (fr) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Modules peptidiques agrafes permeables aux cellules pour administration cellulaire
EP3765852A1 (fr) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Peptides stabilisés de détection de biomarqueurs
JP6500318B2 (ja) * 2018-04-04 2019-04-17 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
WO2020060975A1 (fr) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides sélectifs pour des protéines de la famille bcl-2
AU2020258482A1 (en) 2019-04-18 2021-10-14 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
CN110668933B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-7）的方法
CN110759824B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-3）的方法
US20230116760A1 (en) 2019-12-16 2023-04-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (fr) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Peptides type peptide 1 apparenté au glucagon structuralement stabilisés et leurs utilisations
US20240124529A1 (en) 2020-03-04 2024-04-18 Dana-Farber Cancer Institute, Inc. ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
EP4139360A1 (fr) 2020-04-22 2023-03-01 Dana-Farber Cancer Institute, Inc. Peptides de type hélice 1 d'ace2 antiviraux structuralement stabilisés et leurs utilisations
AU2021262752A1 (en) 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
US20230330238A1 (en) 2020-10-14 2023-10-19 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
US20240002450A1 (en) 2020-11-05 2024-01-04 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
KR20240052851A (ko) 2021-09-08 2024-04-23 다나-파버 캔서 인스티튜트 인크. 항바이러스성의 구조적으로 스테이플링된 SARS-CoV-2 펩티드-콜레스테롤 접합체 및 이의 용도
EP4518900A1 (fr) 2022-05-04 2025-03-12 Dana-Farber Cancer Institute, Inc. Peptides de glycoprotéines de surface d'ebolavirus, conjugués et utilisations de ceux-ci

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3963805A (en) 1974-10-30 1976-06-15 Union Carbide Corporation Water swellable poly(alkylene oxide)
NZ193222A (en) 1979-03-21 1984-08-24 M P Embrey Controlled release composition
JPS585320A (ja) 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
WO1993024476A1 (fr) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Vehicules polymeres solubles dans l'eau servant a la liberation de medicaments
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
WO1996020012A2 (fr) 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Procedes de preparation et de purification de conjugues macromoleculaires
EP0842209B1 (fr) 1995-07-28 2006-10-11 Genzyme Corporation Hydrogels multiblocs biodegradables destines a etre utilises comme agents de liberation regulee pour l'administration de medicaments et le traitement de tissus
WO1997008215A1 (fr) * 1995-08-23 1997-03-06 Mitsui Petrochemical Industries, Ltd. Acrylates nouveaux, ethers d'allyle nouveaux, carbonates d'allyle nouveaux, polymeres d'acrylates, polymeres d'ether d'allyle, polymeres de carbonate d'allyle et polyelectrolytes solides
ZA978537B (en) * 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK1053019T3 (da) * 1998-01-07 2004-04-13 Debio Rech Pharma Sa Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra
US6326276B1 (en) * 1999-08-10 2001-12-04 United Microelectronics Corp. Method for forming a capacitor in dram

Also Published As

Publication number Publication date
CA2316834A1 (fr) 1999-07-15
WO1999034833A9 (fr) 2005-03-17
US7214388B2 (en) 2007-05-08
PT1053019E (pt) 2004-04-30
ATE255422T1 (de) 2003-12-15
EP1053019A1 (fr) 2000-11-22
JP2003510375A (ja) 2003-03-18
WO1999034833A1 (fr) 1999-07-15
US20010016624A1 (en) 2001-08-23
US7166304B2 (en) 2007-01-23
US20040086992A1 (en) 2004-05-06
AU2221499A (en) 1999-07-26
DE69913316D1 (de) 2004-01-15
US20120195846A1 (en) 2012-08-02
US8497357B2 (en) 2013-07-30
US6362276B1 (en) 2002-03-26
DE69913316T2 (de) 2004-11-18
CA2316834C (fr) 2006-01-03
US20110009589A1 (en) 2011-01-13
ES2211033T3 (es) 2004-07-01
US20040086991A1 (en) 2004-05-06
US20070292931A1 (en) 2007-12-20
EP1053019B1 (fr) 2003-12-03
AU755051B2 (en) 2002-12-05
JP3786832B2 (ja) 2006-06-14

Similar Documents

Publication Publication Date Title
DK1053019T3 (da) Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra
PT1028753E (pt) Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis
CA2323048A1 (fr) Derives de poly(ethylene glycol) avec groupes reactifs proximaux
ES2121180T3 (es) Sintesis mejorada de conjugados de polimero/sustancia bioactiva.
DE69809457D1 (de) Ballons aus flüssigkristallinen polymermischungen
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
CA2268433A1 (fr) Produits de conjugaison ameliores d'un interferon avec un polymere
NZ337845A (en) Non-antigenic branched polymer conjugates
CA2255637A1 (fr) Conjugues d'acide cis-docosahexaenoique et de paclitaxel
AU3470600A (en) Compositions and methods for drug delivery
HK1049997A1 (en) Cytotoxic agents comprising taxanes and their therapeutic use
DK97987A (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
DK0621880T3 (da) Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys
AU8090294A (en) Non-antigenic branched polymer conjugates
DE69329903D1 (de) Bioabbaubare polymere zur zelltransplantation
EP1003526A4 (fr) N, o-carboxymethyl-chitosane a liaison covalente et ses applications
AU3483497A (en) Solid solution of an antifungal agent with enhanced bioavailability
DE69315319D1 (de) Gallensäuren-Binde
GT200200038A (es) Conjugados peg de hgf-nk4
EP0838224A3 (fr) Conjugués de polymère - médicament avec in lien clivable par des enzymes
AU2745297A (en) Methods for sterilizing male mammals
AU6889196A (en) Long active composition for rectal administration
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
AU8075098A (en) Tree resistant cable
WO2000072802A3 (fr) Composes hydrosolubles multi-biotine
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载